Skip to main content

Boston Scientific Corp(BSX-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low71.08
Day High72.94
Open:72.90
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

TOP STORIES: Boston Scientific Corp

Select a category then submit the form to load news
Tipranks
Boston Scientific’s ENTRUST Registry Targets Real-World Edge in Carotid Stroke Prevention
Tipranks
UBS Sticks to Their Buy Rating for Boston Scientific (BSX)
Motley Fool
3 Reasons Boston Scientific Stock Could Quietly 5X as the World Ages
StockStory
1 Healthcare Stock to Target This Week and 2 Facing Challenges
BSX
StockStory
Boston Scientific (BSX): Buy, Sell, or Hold Post Q4 Earnings?
BSX
Newsfile
Levi & Korsinsky Investigates Possible Securities Fraud by Boston Scientific Corporation (BSX)
StockStory
1 Oversold Stock Ready to Bounce Back and 2 Facing Challenges
ANGI
Tipranks
Boston Scientific Secures New Credit Facilities for Acquisition
StockStory
Q4 Earnings Highlights: Boston Scientific (NYSE:BSX) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks
BSX
Tipranks
Boston Scientific Expands Board and Boosts Share Buybacks
Newsfile
Ongoing Investigation into Boston Scientific Corporation (BSX): Contact Levi & Korsinsky About Potential Fraud
Tipranks
BTIG Reaffirms Their Buy Rating on Boston Scientific (BSX)
Tipranks
Boston Scientific’s TheraSphere Trial in Japan Signals New Growth Path in Liver Cancer
Zacks Investment Research
BSX vs. ABT: Which MedTech Stock is the Better Investment Now?
BSX vs. ABT: Which MedTech Stock is the Better Investment Now?
Motley Fool
ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing
Newsfile
Ongoing Investigation: Boston Scientific Corporation (BSX) May Have Misled Shareholders - Levi & Korsinsky Investigates
Tipranks
Boston Scientific’s OPTION-EMEA Trial Targets One-Stop AF and Stroke Protection
Tipranks
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Neurocrine (NBIX) and Dexcom (DXCM)
Zacks Investment Research
J&J's MedTech Shows Strong Growth in 2025: Will 2026 be Better?
J&J's MedTech Shows Strong Growth in 2025: Will 2026 be Better?
StockStory
3 S&P 500 Stocks Worth Investigating
TT
Zacks Investment Research
Will ISRG's R&D Focus Following Solid Earnings Growth Drive Demand?
Will ISRG's R&D Focus Following Solid Earnings Growth Drive Demand?
Tipranks
Analysts Offer Insights on Healthcare Companies: Soligenix (SNGX) and Boston Scientific (BSX)
Zacks Investment Research
BSX Posts Q4 Earnings: Should You Buy, Sell or Hold the Stock?
BSX Posts Q4 Earnings: Should You Buy, Sell or Hold the Stock?
Tipranks
Boston Scientific (BSX) Gets a Buy from BTIG
StockStory
The Top 5 Analyst Questions From Boston Scientific’s Q4 Earnings Call
BSX
Tipranks
Analysts Offer Insights on Healthcare Companies: Contineum Therapeutics, Inc. Class A (CTNM) and Boston Scientific (BSX)
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: Cytokinetics (CYTK), Boston Scientific (BSX)
Tipranks
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Viatris (VTRS)
Newsfile
Levi & Korsinsky Investigates Possible Securities Fraud by Boston Scientific Corporation (BSX)
Newsfile
Fraud Investigation Opened: Levi & Korsinsky Investigates Boston Scientific Corporation (BSX) on Behalf of Shareholders
StockStory
3 Safe-and-Steady Stocks to Consider Right Now
INTU
Tipranks
Bernstein Reaffirms Their Buy Rating on Boston Scientific (BSX)

Profile

Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.